Bisphosphonates vs infliximab in ankylosing spondylitis treatment

Rheumatology (United Kingdom)

Volumn 53, Issue 1, 2014, Pages 90-94

  Viapiana, Ombretta ^a   Gatti, Davide ^a   Idolazzi, Luca ^a   Fracassi, Elena ^a   Adami, Silvano ^a   Troplini, Sonila ^a   Povino, Maria Rosaria ^a   Rossini, Maurizio ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

Ankylosing spondylitis; Bisphosphonates; Infliximab; Neridronate

Indexed keywords

C REACTIVE PROTEIN; HLA B27 ANTIGEN; INFLIXIMAB; NERIDRONIC ACID;

ACUTE PHASE RESPONSE; ADULT; ANKYLOSING SPONDYLITIS; ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BONE DENSITY; BONE TURNOVER; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; FEMALE; FEVER; HUMAN; HYPOTENSION; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYALGIA; OPEN STUDY; OSTEOPENIA; OSTEOPOROSIS; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; VISUAL ANALOG SCALE;

ANKYLOSING SPONDYLITIS; BISPHOSPHONATES; INFLIXIMAB; NERIDRONATE;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PAIN MEASUREMENT; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84890893834     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket321     Document Type: Article

References (20)

1. Zochling J, van der Heijde D, Burgos-Vargas R et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006;65:442-52.
2. Sieper J. Developments in therapies for spondyloarthritis. Nat Rev Rheumatol 2012;8:280-7.
3. Harre U, Schett G. Bone research in 2012: the ups and downs of bone in health and rheumatic disease. Nat Rev Rheumatol 2013;9:67-8.
4. Toussirot E, Wendling D. Antiinflammatory treatment with bisphosphonates in ankylosing spondylitis. Curr Opin Rheumatol 2007;19:340-5.
5. Maksymowych WP, Jhangri GS, Fitzgerald AA et al. A sixmonth randomized, controlled, double-blind, doseresponse comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 2002;46:766-73.
6. Maksymowych WP, Lambert R, Jhangri GS et al. Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate therapy. J Rheumatol 2001;28:144-55.
7. Haibel H, Brandt J, Rudwaleit M et al. Treatment of active ankylosing spondylitis with pamidronate. Rheumatology 2003;42:1018-20.
8. Gatti D, Antoniazzi F, Prizzi R et al. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res 2005;20:758-63.
9. Rossini M, Adami S, Viapiana O et al. Circulating gd T cells and the risk of acute-phase response after zoledronic acid administration. J Bone Miner Res 2012;27:227-30.
10. Rossini M, Adami S, Viapiana O et al. Long-term effects of amino-bisphosphonates on circulating gd T cells. Calcif Tissue Int 2012;91:395-9.
11. Maksymowych WP, Chiowchanwisawakit P, Clare T et al. Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis evidence of a relationship between inflammation and new bone formation. Arthritis Rheum 2009;60:93-102.
12. Grover R, Shankar S, Aneja R et al. Treatment of ankylosing spondylitis with pamidronate: an open label study. Ann Rheum Dis 2006;65:688-9.
13. Gatti D, Viapiana O, Idolazzi L et al. Neridronic acid for the treatment of bone metabolic diseases. Expert Opin Drug Metab Toxicol 2009;5:1305-11.
14. Adami S, Gatti D, Colapietro F et al. Intravenous neridronate in adults with osteogenesis imperfecta. J Bone Miner Res 2003;18:126-30.
15. Varenna M, Adami S, Rossini M et al. Treatment of complex regional pain syndrome type I with neridronate: a randomized, double-blind, placebo-controlled study. Rheumatology 2013;52:534-42.
16. Schett G, Coates LC, Ash ZR et al. Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future. Arthritis Res Ther 2011;13(Suppl. 1):S4.
17. Schett G. Structural bone changes in spondyloarthritis: mechanisms, clinical impact and therapeutic considerations. Am J Med Sci 2011;341:269-71.
18. Daoussis D, Andonopoulos AP. The emerging role of Dickkopf-1 in bone biology: is it the main switch controlling bone and joint remodeling? Semin Arthritis Rheum 2011;41:170-7.
19. Gatti D, Viapiana O, Adami S et al. Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin. Bone 2012;50:739-42.
20. Whitaker M, Guo J, Kehoe T et al. Bisphosphonates for osteoporosis-where do we go from here? N Engl J Med 2012;366:2048-51.